International Stem Cell Corp. (OTCMKTS:ISCO – Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 16,612 shares, a growth of 93.5% from the April 30th total of 8,585 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average trading volume of 4,812 shares, the days-to-cover ratio is presently 3.5 days.
International Stem Cell Stock Up 3.9%
Shares of ISCO stock traded up $0.01 on Wednesday, reaching $0.18. The company had a trading volume of 1,000 shares, compared to its average volume of 6,113. The stock has a market capitalization of $1.41 million, a PE ratio of -2.94 and a beta of 0.07. International Stem Cell has a one year low of $0.11 and a one year high of $0.27. The business’s 50-day moving average is $0.16 and its 200 day moving average is $0.15.
International Stem Cell (OTCMKTS:ISCO – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The company had revenue of $2.32 million for the quarter.
About International Stem Cell
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Further Reading
- Five stocks we like better than International Stem Cell
- What IBM’s $10-Billion Quantum Project Means For Smaller Players
- HIVE Earnings Highlight AI Ambitions Beyond Bitcoin Mining
- Microsoft Build 2026 Is Really Just One Big AI Stress Test
- Slice of the Pie: Why Yum’s Deal Lifts QSR
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
